Literature DB >> 17963256

Longitudinal assessment of cognitive characteristics in Costello syndrome.

Marni E Axelrad1, Linda Nicholson, Deborah L Stabley, Katia Sol-Church, Karen W Gripp.   

Abstract

Costello syndrome encompasses pre- and postnatal medical problems including polyhydramnios, failure to thrive, cardiac complications, and an increased risk for solid tumors. Hypotonia and developmental delay are typical in infancy, and mental retardation can be diagnosed in older patients. Previous studies on the cognitive development in Costello syndrome relied on clinically diagnosed cases. The recent discovery of heterozygous HRAS mutations allows for molecular confirmation of the clinical diagnoses. We report here on cognitive abilities and adaptive behavior in the first cohort of patients with molecularly confirmed diagnoses. Further, this is the first longitudinal assessment of cognitive function in this patient population. Sixteen patients with identified HRAS mutations were tested, and 14 completed the Leiter International Performance Scale-Revised. The mean Full-Scale IQ score of 57 (range 30-87) was within the range of mild Mental Retardation. Analysis of test component subsets showed a relative strength in Fluid Reasoning with a mean score of 69 (range 48-98), in the mild range of Mental Retardation. Longitudinal analysis was performed for 12 patients by comparison of data obtained at the first evaluation (T1) to results obtained 2 years later (T2). In these patients intellectual and language abilities remained stable, and no deterioration was seen. We have thus shown that Costello syndrome is a static condition regarding intellectual and language abilities. The Leiter-R Memory Screen indicated functioning in the mildly delayed range for the majority of patients. Adaptive behavior was evaluated using the Vineland tool, and longitudinal data comparison for adaptive behavior showed improvements in Daily Living Skills, Communication, and the Adaptive Behavior Composite. However, these results must be interpreted cautiously as the measuring tool was updated from T1 to T2. Receptive language skills were measured with the Peabody Picture Vocabulary Test-III, showing a mean receptive vocabulary standard score of 65 (SD 15) in the Extremely Low range. Expressive language skills, as measured by the Expressive Vocabulary Test (EVT), scored a mean of 51 (SD 14), in the Extremely Low range. However, half of the subjects obtained the lowest possible score on the EVT, demonstrating that this is not the ideal tool for use in this patient population. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17963256     DOI: 10.1002/ajmg.a.31968

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  12 in total

Review 1.  High incidence of progressive postnatal cerebellar enlargement in Costello syndrome: brain overgrowth associated with HRAS mutations as the likely cause of structural brain and spinal cord abnormalities.

Authors:  Karen W Gripp; Elizabeth Hopkins; Daniel Doyle; William B Dobyns
Journal:  Am J Med Genet A       Date:  2010-05       Impact factor: 2.802

2.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

3.  Effects of germline mutations in the Ras/MAPK signaling pathway on adaptive behavior: cardiofaciocutaneous syndrome and Noonan syndrome.

Authors:  Elizabeth I Pierpont; Mary Ella Pierpont; Nancy J Mendelsohn; Amy E Roberts; Erica Tworog-Dube; Katherine A Rauen; Mark S Seidenberg
Journal:  Am J Med Genet A       Date:  2010-03       Impact factor: 2.802

4.  Phenotypic spectrum of Costello syndrome individuals harboring the rare HRAS mutation p.Gly13Asp.

Authors:  Débora Bertola; Michelle Buscarilli; Deborah L Stabley; Laura Baker; Daniel Doyle; Dennis W Bartholomew; Katia Sol-Church; Karen W Gripp
Journal:  Am J Med Genet A       Date:  2017-04-03       Impact factor: 2.802

5.  Age-related differences in prevalence of autism spectrum disorder symptoms in children and adolescents with Costello syndrome.

Authors:  David D Schwartz; Jennifer M Katzenstein; Eric J Highley; Deborah L Stabley; Katia Sol-Church; Karen W Gripp; Marni E Axelrad
Journal:  Am J Med Genet A       Date:  2017-04-04       Impact factor: 2.802

6.  Longitudinal assessment of intellectual abilities of children with Williams syndrome: multilevel modeling of performance on the Kaufman Brief Intelligence Test-Second Edition.

Authors:  Carolyn B Mervis; Doris J Kistler; Angela E John; Colleen A Morris
Journal:  Am J Intellect Dev Disabil       Date:  2012-03

7.  Oligodendrocyte RasG12V expressed in its endogenous locus disrupts myelin structure through increased MAPK, nitric oxide, and notch signaling.

Authors:  Haley E Titus; Alejandro López-Juárez; Sadiq H Silbak; Tilat A Rizvi; Madeleine Bogard; Nancy Ratner
Journal:  Glia       Date:  2017-08-30       Impact factor: 7.452

8.  Autism traits in the RASopathies.

Authors:  Brigid Adviento; Iris L Corbin; Felicia Widjaja; Guillaume Desachy; Nicole Enrique; Tena Rosser; Susan Risi; Elysa J Marco; Robert L Hendren; Carrie E Bearden; Katherine A Rauen; Lauren A Weiss
Journal:  J Med Genet       Date:  2013-10-07       Impact factor: 6.318

9.  Verbal memory functioning in adolescents and young adults with Costello syndrome: evidence for relative preservation in recognition memory.

Authors:  David D Schwartz; Jennifer M Katzenstein; Elisabeth Hopkins; Deborah L Stabley; Katia Sol-Church; Karen W Gripp; Marni E Axelrad
Journal:  Am J Med Genet A       Date:  2013-08-05       Impact factor: 2.802

10.  Longitudinal course of cognitive, adaptive, and behavioral characteristics in Costello syndrome.

Authors:  Marni E Axelrad; David D Schwartz; Julie E Fehlis; Elizabeth Hopkins; Deborah L Stabley; Katia Sol-Church; Karen W Gripp
Journal:  Am J Med Genet A       Date:  2009-12       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.